Clinical Trials Logo

Clinical Trial Summary

This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor-positive (HR+) metastatic breast cancer.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05064085
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Status Recruiting
Phase Phase 1
Start date September 28, 2021
Completion date September 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04942054 - A Study in Patients With Advanced Breast Cancer Phase 1
Not yet recruiting NCT05020860 - Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer Phase 2
Not yet recruiting NCT04997941 - Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients Phase 2
Not yet recruiting NCT04891731 - Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
Completed NCT01177397 - Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Phase 1/Phase 2